November 21, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Checkpoint Therapeutics, Inc. | |
| Registration Statement on Form S-3 | ||
| File No. 333-275644 |
Ladies and Gentlemen:
Checkpoint Therapeutics, Inc. (the “Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:00 p.m. EST on November 24, 2023, or as soon thereafter as practicable.
Please contact Matt Mamak of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
| Checkpoint Therapeutics, Inc. | ||
| By: | /s/ James F. Oliviero | |
| Name: James F. Oliviero | ||
| Title: Chief Executive Officer and President | ||